\\ \title{

## FY4/14<br> \title{ \section*{FY4/14 <br> <br> Results Briefing 

 <br> <br> Results Briefing}


AIN PHARMACIEZ INC.
June 5,2014

## Result Overview

The Group reported net sales of $¥ 170,225$ million, an increase of $10.1 \%$ year on year, reflecting the opening of new dispensing pharmacies and M\&As. Ordinary income rose $2.9 \%$ to $¥ 10,587$ million and net income increased $3.6 \%$ year on year to $¥ 5,259$ million.

| ( million) | FY4/13 results | $\begin{gathered} \text { FY4/14 } \\ \text { plan } \end{gathered}$ | FY4/14 results | YoY change | $\begin{gathered} \text { YoY } \\ \text { change(\%) } \end{gathered}$ | ${ }_{\substack{\text { Vsplan } \\(\%)}}^{(1.0)}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 154,560 | 172,000 | 170,225 | +15,665 | +10.1 | (1.0) |
| Gross profit \% of net sales | $\begin{array}{r} 24,442 \\ 15.8 \end{array}$ | $\begin{array}{r} 26,960 \\ 15.7 \end{array}$ | $\begin{array}{r} 25,748 \\ 15.1 \end{array}$ | +1,306 | +5.3 | (4.5) |
| SG\&A expenses $\%$ of net sales | $\begin{array}{r} 14,740 \\ 9.5 \end{array}$ | $\begin{array}{r} 15,680 \\ 9.1 \end{array}$ | $\begin{array}{r} 15,635 \\ 9.2 \end{array}$ | +895 | +6.1 | (0.3) |
| Operating income $\%$ of net sales | $\begin{array}{r} 9,701 \\ 6.3 \end{array}$ | $\begin{array}{r} 11,280 \\ 6.6 \end{array}$ | $\begin{array}{r} 10,113 \\ 5.9 \end{array}$ | +412 | +4.2 | (10.3) |
| Ordinary income \% of net sales | $\begin{array}{r} 10,292 \\ 6.7 \end{array}$ | $\begin{array}{r} 11,650 \\ 6.8 \end{array}$ | $\begin{array}{r} 10,587 \\ 6.2 \end{array}$ | +295 | +2.9 | (9.1) |
| Net income \% of net sales | $\begin{array}{r} 5,075 \\ 3.3 \\ \hline \end{array}$ | $\begin{array}{r} 6,000 \\ 3.5 \\ \hline \end{array}$ | $\begin{array}{r} 5,259 \\ 3.1 \\ \hline \end{array}$ | +184 | +3.6 | (12.3) |
| Net income per share(羊) | 318.37 | 376.31 | 330.08 | +11.71 | +3.7 | (12.3) |

Figures in the table are rounded down

## Dispensing Pharmacy Business(Consolidated)

The dispensing pharmacy business reported net sales of $¥ 151,472$ million, an increase of $10.3 \%$ year on year, and segment income of $¥ 12,772$ million, up $0.9 \%$.

| ( $¥$ million) | FY4/13 results | $\begin{gathered} \text { FY4/14 } \\ \text { plan } \end{gathered}$ | FY4/14 results | YoY change | YoY change(\%) | $\begin{gathered} \text { Vs plan } \\ (\%) \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 137,291 | 152,650 | 151,472 | +14,181 | +10.3 | (0.8) |
| Gross profit <br> $\%$ of net sales | $\begin{array}{r} 19,413 \\ 14.1 \end{array}$ | $\begin{array}{r} 21,320 \\ 14.0 \end{array}$ | $\begin{array}{r} 20,297 \\ 13.4 \end{array}$ | +884 | +4.6 | (4.8) |
| SG\&A expenses <br> $\%$ of net sales | $\begin{array}{r} 7,306 \\ 5.3 \end{array}$ | $\begin{array}{r} 7,960 \\ 5.2 \end{array}$ | $\begin{array}{r} 8,018 \\ 5.3 \end{array}$ | +712 | +9.7 | +0.7 |
| Operating income <br> \% of net sales | $\begin{array}{r} 12,107 \\ 8.8 \end{array}$ | $\begin{array}{r} 13,360 \\ 8.8 \end{array}$ | $\begin{array}{r} 12,279 \\ 8.1 \end{array}$ | +172 | +1.4 | (8.1) |
| Segment income \% of net sales | $\begin{array}{r} 12,655 \\ 9.2 \\ \hline \end{array}$ | $\begin{array}{r} 13,630 \\ 8.9 \\ \hline \end{array}$ | $\begin{array}{r} 12,772 \\ 8.4 \\ \hline \end{array}$ | +117 | +0.9 | (6.3) |
| Number of stores | 560 | 640 | 616 | +56 | +10.0 | (3.7) |

$\Rightarrow$ Figures in the table are rounded down
$\Rightarrow$ Segment income is adjusted ordinary income shown on the quarterly consolidated statements of income

- Prescription volume:+6.8\% YoY
- Average prescription price:+3.3\% YoY


## Of Drug and Cosmetic Store Business(Consolidated)

The drug and cosmetic store business reported net sales of $¥ 17,985$ million, an increase of $7.5 \%$ year on year, and segment income of $¥ 23$ million, up $65.8 \%$.

| ( $\ddagger$ million) | FY4/13 results | $\begin{gathered} \mathrm{FY} 4 / 14 \\ \text { plan } \end{gathered}$ | FY4/14 results | $\begin{gathered} \text { YoY } \\ \text { change } \end{gathered}$ |  | $\underset{\substack{\text { Vs plan } \\(\%)}}{ }$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 16,735 | 18,430 | 17,985 | +1,250 | +7.5 | (2.4) |
| Gross profit $\%$ of net sales | $5,283$ | $\begin{array}{r} 5,730 \\ 31.1 \end{array}$ | $5,668$ | +385 | +7.3 | (1.1) |
| SG\&A expenses <br> $\%$ of net sales | $\begin{array}{r} 5,351 \\ 32.0 \end{array}$ | $\begin{array}{r} 5,670 \\ 30.8 \end{array}$ | $\begin{array}{r} 5,685 \\ 31.6 \end{array}$ | +334 | +6.2 | +0.3 |
| Operating income $\%$ of net sales | (68) | 60 0.3 | (17) | +51 | - |  |
| Segment income $\%$ of net sales | 14 0.1 | $\begin{array}{r} 150 \\ 0.8 \\ \hline \end{array}$ | $\begin{array}{r} 23 \\ 0.1 \end{array}$ | +9 | +64.3 | (84.7) |
| Number of stores | 61 | 67 | 59 | (2) | (3.3) | (11.9) |

- Figures in the table are rounded down

Segment income is adjusted ordinary income shown on the quarterly consolidated statements of income

## Consolidated B/S

The shareholders' equity ratio improved 1.5 percentage points to $41.5 \%$, compared with $40.0 \%$ at the end of the previous fiscal year.
( $¥$ million)

| End-FY4/13 |  |  |  |
| :---: | :---: | :---: | :---: |
| Assets |  | Liabilities |  |
| Current assets Cash on hand and in banks | $\begin{array}{r} 43,162 \\ 18,460 \end{array}$ | Current liabilities | 45,686 |
|  |  | Short-term debt | 7,483 |
|  |  | Lease obligations | 498 |
| Fixed assets <br> Investments in securities | $\begin{array}{r} 52,676 \\ 2,789 \end{array}$ | Long-term liabilifies | 11,796 |
|  |  | Long-term debt | 8,048 |
|  |  | Lease obligations | 1,223 |
| Deferred assets | 1 | Total net assets | 38,356 |
| Total assets | 95,839 | Total liabilities and net assets | 95,839 |
| Net cash |  |  | 1,206 |
| Shareholders' equity ratio(\%) |  |  | 40.0 |
| - Figures in the table are rounded down |  |  |  |
| - Net cash = Cash on hand and in banks-Interest-bearing d |  |  |  |

( $¥$ million)

| End-FY4/14 |  |  |  |
| :---: | :---: | :---: | :---: |
| Assets |  | Liabilities |  |
| Current assets <br> Cash on hand and in banks | $\begin{array}{r} 44,334 \\ 18,846 \end{array}$ | Current liabilities | 50,349 |
|  |  | Short-erm debt | 6,535 |
|  |  | Lease obligations | 566 |
| Fixed assets <br> Investments in securities | $\begin{array}{r} 57,048 \\ 2,559 \end{array}$ | Long-term liabilities | 8,793 |
|  |  | Long-term debt | 4,502 |
|  |  | Lease obligations | 1,454 |
| Deferred assets | 101,382 | Total net assets | 42,240 |
| Total assets |  | Total liabilities and net assets | 101,382 |
| Net cash |  |  | 5,787 |
| Shareholders' equity ratio(\%) |  |  | 41.5 |

Consolidated current assets at the end of the fiscal year under review increased by $¥ 1,172$ million to $¥ 44,334$ million compared to $¥ 43,162$ million at the end of the previous fiscal year. Fixed assets at the end of the fiscal year under review increased by $¥ 4,371$ million to $¥ 57,048$ million compared to $¥ 52,676$ million at the end of the previous fiscal year.

| ( $¥$ million) | End-FY4/12 | End-FY4/13 | End-FY4/14 | Change |
| :--- | ---: | ---: | ---: | ---: |
| Cash on hand and in banks | 15,935 | 18,460 | 18,846 | +386 |
| Notes and accounts receivable | 10,985 | 7,043 | 6,718 | $(325)$ |
| Inventories | 8,253 | 7,944 | 9,759 | $+1,815$ |
| Total current assets | $\mathbf{4 0 , 3 2 0}$ | $\mathbf{4 3 , 1 6 2}$ | $\mathbf{4 4 , 3 3 4}$ | $\mathbf{+ 1 , 1 7 2}$ |
| Buildings and structures, net | 7,048 | 8,247 | 9,962 | $+1,715$ |
| Land | 5,621 | 6,030 | 6,698 | +668 |
| Lease assets | 873 | 1,229 | 1,342 | +113 |
| Total property,plant and equipment | $\mathbf{1 5 , 2 5 6}$ | $\mathbf{1 7 , 5 5 0}$ | $\mathbf{1 9 , 5 8 3}$ | $\mathbf{+ 2 , 0 3 3}$ |
| lease assets | 113 | 99 | 47 | $\mathbf{( 5 2 )}$ |
| Total intangible fixed assets | $\mathbf{1 8 , 6 5 5}$ | $\mathbf{2 0 , 6 0 5}$ | $\mathbf{2 1 , 1 2 9}$ | $\mathbf{+ 5 2 4}$ |
| Investments in securities | 2,825 | 2,789 | 2,559 | $(230)$ |
| Deferred tax assets | 1,122 | 946 | 1,068 | $\mathbf{+ 1 2 2}$ |
| Lease and guarantee deposits | 5,758 | 6,985 | 8,081 | $\mathbf{+ 1 , 0 9 6}$ |
| Total investments and other assets | $\mathbf{1 1 , 6 5 7}$ | $\mathbf{1 4 , 5 2 0}$ | $\mathbf{1 6 , 3 3 4}$ | $\mathbf{+ 1 , 8 1 4}$ |
| Total fixed assets | $\mathbf{4 5 , 5 7 0}$ | 52,676 | 57,048 | $\mathbf{+ 4 , 3 7 2}$ |
| Total assets | $\mathbf{8 5 , 9 0 8}$ | 95,839 | $\mathbf{1 0 1 , 3 8 2}$ | $\mathbf{+ 5 , 5 4 3}$ |

Figures in the table are rounded down
Change( $¥$ ):End-FY4/14compared with end-FY4/13

- Capital expenditures (Purchases of property, plant and equipment and intangible fixed assets + deposits/guarantees) totaled $¥ 6,328$ million

Liabilities increased by $¥ 1,659$ million to $¥ 59,142$ million compared to $¥ 57,483$ million at the end of the previous fiscal year. This primarily reflected accounts payable of $¥ 28,002$ million, up $¥ 3,917$ million year on year, short-term debt of $¥ 6,535$ million, down $¥ 947$ million, and long-term debt of $¥ 4,502$ million, down $¥ 3,545$ million.

| ( $¥$ million) | End-FY4/12 | End-FY4/13 | End-FY4/14 | Change |
| :---: | :---: | :---: | :---: | :---: |
| Accounts payable | 22,524 | 24,084 | 28,002 | +3,918 |
| Short-term debt | 6,397 | 7,483 | 6,535 | (948) |
| Lease obligation | 344 | 498 | 566 | +68 |
| Total current liabilities | 42,945 | 45,686 | 50,349 | +4,663 |
| Long-term debt(including bonds) | 6,318 | 8,048 | 4,502 | $(3,546)$ |
| Lease obligation | 675 | 1,223 | 1,454 | +231 |
| Total long-term liabilities | 9,216 | 11,796 | 8,793 | $(3,003)$ |
| Total liabilities | 52,162 | 57,483 | 59,142 | +1,659 |
| Common stock | 8,682 | 8,682 | 8,682 | 0 |
| Capital surplus | 7,872 | 7,872 | 7,872 | 0 |
| Retained earnings | 17,426 | 21,704 | 26,007 | +4,303 |
| Total shareholders' equity | 33,976 | 38,254 | 42,146 | +3,892 |
| Total net assets | 33,745 | 38,356 | 42,240 | +3,884 |
| Total liabilities and net assets | 85,908 | 95,839 | 101,382 | +5,543 |

Figures in the table are rounded down
$>$ Change( $¥$ ): End-FY4/14 compared with end-FY4/13

Cash and cash equivalents increased $¥ 296$ million year on year to $¥ 18,735$ million.
( $¥$ million)

End-FY4/13 End-FY4/14 Change

| Net cash provided by operating activities | 10,203 | 14,662 | +4,459 |
| :---: | :---: | :---: | :---: |
| Income before income taxes and minority interests | 9,694 | 10,265 | +571 |
| Depreciation and amortization | 2,212 | 2,258 | +46 |
| Amortization of goodwill | 1,784 | 2,033 | +249 |
| Decrease in accounts receivable | 4,672 | 1,110 | $(3,562)$ |
| (Increase) decrease in inventories | 504 | $(1,485)$ | $(1,989)$ |
| (Increase) decrease in other accounts receivable | $(4,268)$ | 1,551 | 5,819 |
| Net cash used in investing activities | $(8,503)$ | $(7,749)$ | +754 |
| Payments for purchases of property, plant and equipment, and intangible fixed assets | $(4,223)$ | $(4,254)$ | (31) |
| Purchase of shares in affiliated companies | $(2,923)$ | $(2,410)$ | +513 |
| Net cash provided by (used in) financing activities | 803 | $(6,617)$ | $(7,420)$ |
| Net increase in cash and cash equivalents | 2,504 | 295 | $(2,209)$ |
| Cash and cash equivalents at end of the period | 18,439 | 18,735 | +296 |

Figures in the table are rounded down

## Business Value Analysis

|  | End-FY4/12 | End-FY4/13 | End-FY4/14 | Change |
| :---: | :---: | :---: | :---: | :---: |
| Shareholders' equity ratio (\%) | 39.2 | 40.0 | 41.5 | +1.5 |
| Market value equity ratio (\%) | 79.6 | 79.3 | 70.3 | (9.0) |
| PER (times) | 13.96 | 14.97 | 13.62 | (1.35) |
| EPS ( $~(~) ~$ | 307.35 | 318.37 | 330.08 | +11.71 |
| PBR (times) | 2.03 | 1.98 | 1.70 | (0.28) |
| BPS ( $*$ ) | 2,113.79 | 2,403.43 | 2,656.86 | +253.43 |
| ROA (\%) | 6.0 | 5.6 | 5.3 | (0.3) |
| ROE (\%) | 15.5 | 14.1 | 13.1 | (1.0) |
| EBITDA (¥ million) | 13,266 | 13,698 | 14,405 | +707 |
| EV/EBITDA (times) | 4.88 | 5.37 | 4.49 | (0.88) |
| Net D/E ratio (imes) | (0.06) | (0.03) | (0.14) | (0.11) |
| Net cash ( $¥$ million) | 2,199 | 1,206 | 5,787 | +4,581 |
| Shareholder value ( $¥$ million) | 66,988 | 74,713 | 70,407 | $(4,306)$ |
| Market capitalization (¥ million) | 68,385 | 75,957 | 71,264 | $(4,693)$ |

The Group forecasts net sales for the fiscal year ending April 30, 2015 of $¥ 190,000$ million, up $11.6 \%$ year on year, ordinary income of $¥ 10,700$ million, up $1.1 \%$, and net income of $¥ 5,500$ million, an increase of $4.6 \%$

| ( $\ddagger$ million) | $\begin{aligned} & \text { FY4/13 } \\ & \text { results } \end{aligned}$ | FY4/14 results | $\begin{gathered} \text { FY4/15 } \\ \text { plan } \end{gathered}$ | YoY change | YoY change (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 154,560 | 170,225 | 190,000 | +19,775 | +11.6 |
| Gross profit \% of net sales | $\begin{array}{r} 24,442 \\ 15.8 \end{array}$ | $\begin{array}{r} 25,748 \\ 15.1 \end{array}$ | $\begin{array}{r} 27,870 \\ 14.7 \end{array}$ | +2,122 | +8.2 |
| SG\&A expenses <br> $\%$ of net sales | $\begin{array}{r} 14,740 \\ 9.5 \end{array}$ | $\begin{array}{r} 15,635 \\ 9.2 \end{array}$ | $\begin{array}{r} 17,610 \\ 9.3 \end{array}$ | +1,975 | +12.6 |
| Operating income $\%$ of net sales | $\begin{array}{r} 9,701 \\ 6.3 \end{array}$ | $\begin{array}{r} 10,113 \\ 5.9 \end{array}$ | $\begin{array}{r} 10,260 \\ 5.4 \end{array}$ | +147 | +1.5 |
| Ordinary income $\%$ of net sales | $\begin{array}{r} 10,292 \\ 6.7 \end{array}$ | $\begin{array}{r} 10,587 \\ 6.2 \end{array}$ | $\begin{array}{r} 10,700 \\ 5.6 \end{array}$ | +113 | +1.1 |
| Net income \% of net sales | $\begin{array}{r} 5,075 \\ 3.3 \end{array}$ | $\begin{array}{r} 5,259 \\ 3.1 \end{array}$ | $\begin{array}{r} 5,500 \\ 2.9 \end{array}$ | +241 | +4.6 |
| Net income per share( $¥$ ) | 318.37 | 330.08 | 346.91 | +16.83 | +5.1 |
| Annual dividend ( $¥$ ) | 60.00 | 60.00 | 60.00 | 0.00 | 00.0 |

[^0]
## Inquiries related to this presentation should be addressed to

## AIN PHARMACIEZ INC. Corporate Planning Division <br> TEL(81)11-814-0010 <br> FAX(81)11-814-5550 <br> http://www.ainj.co.jp/

This document may not be reproduced or distributed to any third party without prior approval of AIN PHARMACIEZ INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.


AIN GROUP


[^0]:    $\Rightarrow$ Figures in the table are rounded down

    - Change: FY4/15plan compared with FY4/14

